The 25 most influential people in biopharma today By John Carroll / FierceBiotech

It's no secret that despite a spike in FDA approvals, the biopharma industry has been going through a long and devastating innovation drought. The low rate of new drug approvals threatens the very existence of the pharma business as we know it. Only leaders who can buck that trend--and create one of their own--will survive.
It's against that backdrop that FierceBiotech and FiercePharma present a look at the newsmakers who promise to blaze a trail for others to follow. And it's not just a listing of CEOs. Our report includes an R&D revolutionary, a woman who built her own sizable venture in India, research executives busily mapping new R&D strategies, a developer-turned-university chancellor who has her own views on the brave new world to come and where academics fit into it, along with several others.

Click en cada nombre para ver perfil completo.

Timothy Anderson II Francis Collins Susan Desmond-Hellmann Robert A. Bradway Alex Denner Sir Andrew Dillon Sir Christopher Evans Kenneth Frazier

Richard A. Gonzalez James Greenwood Dr. Margaret Hamburg Yasuchika Hasegawa Joseph Jimenez Jeremy Levin Kiran Mazumdar-Shaw Bernard Munos

Ian Read George Scangos Severin Schwan Moncef Slaoui Lars Rebien Sørensen J. Craig Venter Christopher Viehbacher Tony West Andrew Witty

I wrote part of this report, with Suzanne Elvidge, Mark Hollmer, Ryan McBride and Tracy Staton shouldering the bulk of the work. I'd like some feedback here from readers for next year, when we'll be back with another annual report on influentials. - John Carroll, editor-in-chief

La "Big Pharma" está presente:

Amgen (Bradway), Merck (Frazier), Abbott (Gonzalez), Takeda (Hasegawa), Novartis (Jimenez), Teva (Levin), Pfizer (Read), Biogen (Scangos), Roche (Schwan), Glaxo (Slaoui), Novo (Sorensen), Sanofi (Viehbacher), Glaxo (Witty).